Health and Healthcare
Johnson & Johnson's Impressive Quarter, Still Held Back by One Segment
Published:
Johnson & Johnson (NYSE: JNJ) released its most recent quarterly results before the markets opened on Thursday. For the second quarter, the pharmaceutical giant said that it had $1.67 in earnings per share (EPS) and $18.34 billion in revenue. That compares with consensus estimates of $1.48 in EPS and revenue $17.5 billion, as well as the $2.58 per share and $20.56 billion posted in the same period of last year.
Consumer Health sales decreased 3.4% on an adjusted operational basis to $3.30 billion. This was driven primarily by the COVID-19 pandemic, most notably reflected in skin health and beauty care products, followed by women’s health care products and international baby care products.
Pharmaceutical sales increased 3.9% to $10.75 billion. This increase was driven by Stelara, Darzalex, Imbruvica, Erleada and Tremfya.
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined by 32.5%, driven by the estimated net negative impact of the pandemic and the associated deferral of medical procedures to the company’s Surgery, Orthopaedics, Vision and Interventional Solutions businesses.
Looking ahead to the 2020 full year, Johnson & Johnson expects to see EPS in the range of $7.85 to $8.05 and adjusted operational sales between $81.0 billion and $82.5 billion. Consensus estimates are calling for $7.73 in EPS and $79.54 billion in revenue for the year.
Separately, the company has been accelerating its vaccine hopes with a fair amount of success. Look for results from its Phase 1/2a clinical trial of Ad26.COV2-S in the coming month.
Management noted that the company is continuing to navigate the external landscape successfully and that it remains focused on advancing the development of a vaccine to help address this pandemic and save lives.
Johnson & Johnson stock traded down less than 1% on Thursday, at $147.65 in a 52-week range of $109.16 to $157.00. The consensus price target is $164.24.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
